BioCentury
ARTICLE | Clinical News

RBx 10558: Development discontinued

December 12, 2011 8:00 AM UTC

Furiex discontinued development of PPD-10558 after top-line data from a double-blind, U.S. Phase II trial in about 282 patients showed that twice-daily PPD-10558 for up to 12 weeks missed the primary endpoint of significantly reducing the incidence of treatment stoppage due to SAM vs. both placebo and atorvastatin. Furiex said it was "surprised to see drop-out rates due to muscle symptoms in the placebo treatment group that were comparable to the PPD-10558 and atorvastatin treatment groups." PPD-10558 did significantly reduce LDL-C vs. placebo. The trial enrolled patients with high cholesterol who were previously intolerant to statins due to SAM. ...